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As a result of large-scale sequencing projects and recent splicing-
microarray studies, estimates of mammalian genes expressing
multiple transcripts continue to increase. This expansion of tran-
script information makes it possible to better characterize alter-
native splicing events and gain insights into splicing mechanisms
and regulation. Here, we describe a class of splice sites that we call
dual-specificity splice sites, which we identified through genome-
wide, high-quality alignment of mRNA/EST and genome sequences
and experimentally verified by RT-PCR. These splice sites can be
alternatively recognized as either 5 or 3 splice sites, and the dual
splicing is conceptually similar to a pair of mutually exclusive exons
separated by a zero-length intron. The dual-splice-site sequences
are essentially a composite of canonical 5 and 3 splice-site
consensus sequences, with a CAGGURAG core. The relative use of
a dual site as a 5 or 3 splice site can be accurately predicted by
assuming competition for specific binding between spliceosomal
components involved in recognition of 5 and 3 splice sites,
respectively. Dual-specificity splice sites exist in human and mouse,
and possibly in other vertebrate species, although most sites are
not conserved, suggesting that their origin is recent. We discuss the
implications of this unusual splicing pattern for the diverse mech-
anisms of exon recognition and for gene evolution.
alternative splicing  competition  mRNA/EST
Eukaryotic genes are split into exons and introns, which in thevast majority of cases are marked by a GU dinucleotide (5
splice site) at the exon/intron boundary and an AG dinucleotide (3
splice site) at the intron/exon boundary. To produce a mature
transcript from a pre-mRNA, the introns are spliced out and the
exons are ligated by a large protein/small nuclearRNAcomplex, the
spliceosome (1, 2). The accuracy and efficiency of exon and intron
recognition and splicing are dictated by: (i) primary splicing signals,
including the splice sites, a polypyrimidine tract, and a branch site
(2); (ii) nearby exonic or intronic regulatory sequences acting as
splicing enhancers or silencers (3–5); (iii) spatial and structural
constraints, such as exon and intron size (6, 7) and RNA secondary
structure (8); and (iv) interactions of these cis-acting elements with
splicing factors (9). Any compromise or disruption of these splicing
elements or changes in the levels or properties of the factors may
result in regulated alternative splicing (AS) or aberrant splicing
events (10).
With the availability of genome sequences and a large amount of
mRNA/EST data, especially in human and mouse, genome-wide
bioinformatic analysis has revealed that a majority (60%) of
mammalian genes are alternatively spliced in various patterns (11,
12). Typical types of AS events include exon skipping/inclusion
(cassette exons), alternative 5 or 3 splice sites, mutually exclusive
exon use, intron retention, and various combinations thereof (10).
Despite the complexity of splicing patterns and regulation, in all of
these cases, 5 and 3 splice sites are defined unambiguously and
recognized by distinct sets of spliceosomal components, usually at
the earliest stages of spliceosome assembly (Fig. 1A) (1). The splice
sites have degenerate consensus sequences, although GU and AG
are nearly invariant at the 5 and 3 intronic borders, respectively.
Interestingly, CAGGU defines the consensus sequence of both 5
and 3 splice sites, although with a different extent of degeneracy
(Fig. 1C). This observation raises interesting questions concerning
how the splicing machinery distinguishes 5 and 3 splice sites, and
whether the same site can be used as both a 3 and a 5 splice site.
In this study, we investigate unusual AS events associated with
splice sites that can be used as either 5 or 3 splice sites. We refer
to these sites as dual-specificity splice sites (or dual splice sites). We
detected these dual-specificity sites with high-quality mRNA/EST
and genome sequence alignment evidence. In these cases, a par-
ticular splice site is used as a 3 splice site in some transcripts, and
in other transcripts, the same site is used as a 5 splice site. When
the dual splice site is recognized as a 3 splice site, the sequences
upstream of the site are removed as an intron, whereas the
sequences downstream are retained as an exon. However, this
situation is reversed in alternative isoforms, in which the dual site
is used as a 5 splice site and the sequences downstream of the site
are removed as an intron (Fig. 1B). Thus, the resulting exon/intron
flip-over in different isoforms affects the nature of the protein
products.We validated the occurrence of dual-specificity splicing in
vivo by RT-PCR and direct sequencing and found that the use of
the site as a 5 or 3 splice site can vary in a tissue-specific manner.
Bioinformatic analysis revealed unique features that are consistent
with the dual-specificity character and predictive of the splicing
outcome. The implications for protein coding and gene-structure
evolution are also discussed. We conclude that the use of dual-
specificity splice sites as either a 5 or 3 splice site represents an
additional class of AS.
Results
Identification and Classification of Dual-Specificity Splice Sites. We
built a database of classified AS events (dbCASE), using high-
quality transcripts (mRNA/EST) and genome alignment for mul-
tiple species. A data structure called splicing graph (13) was applied
and extended to efficiently detect various alternative and constitu-
tive splicing events and to track supporting transcripts (seeMaterials
and Methods). During this process, we found that previous data
structure could not represent the transcript data in some cases
because of the presence of dual splice sites. In total, we found 594
human (and 195 mouse) putative dual splice sites with supporting
transcript (mRNA/EST) evidence. We also extracted strictly con-
stitutive exons and introns (in the sense that no violating transcripts
were detected) as a comparative dataset to further analyze the
nature of these dual splice sites.
Because most canonical introns have GU and AG dinucleotides
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at their 5 and 3 termini, respectively (14), we first examined
whether the dual splice sites conform to this AGGU rule. Overall,
155 dual splice sites (26%) conform to the AGGU rule. This
percentage is lower than that expected compared with constitutive
splice sites (Table 1). There are several explanations that may
account for this difference. First, sites with few supporting tran-
scripts may be unreliable because they could reflect aberrant
splicing orRT-PCRerrors. Second, repetitive elements, sequencing
errors in the transcripts (especially ESTs) or in the genome,
polymorphisms, and transcripts from paralogous or pseudo genes
may result in spurious alignments. The third point, which is not
mutually exclusive with the two preceding explanations, is that we
observed 64 human (and 9mouse) genes with clusters of dual splice
sites. These genes seem to be highly conserved across vertebrate
species but are enriched in exonic SNPs (data not shown). They
account for approximately half of the total number of putative dual
splice sites. Most of these sites (85%) do not match the AGGU
pattern, and it is unclear whether they are authentic examples of
dual splice sites or whether they represent artifacts.
To increase the level of confidence in dual-splice-site prediction,
we explored ways to increase the stringency of our criteria for
dual-splice-site classification. The percentage of AGGU sites in-
creased greatly when two or more supporting transcripts were
required for each isoform (Table 1). We also considered gene
transcripts with only one dual splice site (singletons) by removing
all genes with two or more sites, to eliminate potential noise from
other classes of transcripts, as described above. This filtering step
further increased the proportion of AGGU sites. For example, 23
of 26 (88.5%) singleton sites with three or more supporting
transcripts for each isoform conformed to the AGGU pattern; this
percentage is significantly higher compared with constitutive splice
sites (P  0.0006 for 5 splice sites, P  1014 for 3 splice sites,
Fisher’s exact test). Thus, we surmise thatmost authentic dual splice
sites follow the AGGU rule, which is likely an important feature to
specify dual splicing, probably by the U2-type spliceosome (2).
To characterize the features of dual splice sites, we derived a
high-confidence dataset by limiting dual splice sites to AGGU sites
with two or more supporting transcripts for each isoform. We
further removed nine sites from the UBC gene (because this gene
contains multiple repetitive coding units (15), which are prone to
alignment uncertainties) and also three other sites that lacked
perfectly matching alignments in sequences flanking the sites. The
final high-confidence dataset has 36 dual-specificity splice sites
[supporting information (SI) Table 2], which were used for the
analyses below. Among these splice sites, 11 (31%) have RefSeq or
mRNA supporting evidence for both isoforms, whereas the re-
maining 25 (69%) have only ESTs as supporting evidence for one
or both isoforms.
The dual splicing pattern can be classified according to the nature
of the resulting alternative transcripts. The most prevalent class of
dual splice sites is associated with the first exon (12 of 36 cases)
(class I, SI Fig. 5). This is unlikely to be attributable to sequence-
alignment artifacts, because all spurious terminal exons25 ntwere
removed, so that each intron is flanked by two reliable exons.
Instead, this first-exon preference suggests a possible link between
alternative promoters and dual-splice-site choice (SI Fig. 5). Other
dual sites create an upstream or downstream alternative exon (class
II, SI Fig. 6 and class III, SI Fig. 7) or result in intron retention (class
IV, SI Fig. 8) or exon truncation (class V, SI Fig. 9).
Dual Splice Sites Resemble the 5 and 3 Splice Site Consensus
Sequences. To study the specificity of recognition as 5 splice sites
and 3 splice sites more quantitatively, we derived the position
weight matrices (PWMs) of dual splice sites, and canonical 5 and
3 splice sites from constitutive exons (16) (Fig. 1C). Comparedwith
the constitutive splice sites, it is readily discernible that the PWM
of dual splice sites (Fig. 1D) is approximately the juxtaposition of
the intronic portions of the constitutive 5 and 3 splice sitematrices,
with CAGGURAG (R represents A or G) as a core in the
consensus. The GC content around dual splice sites is higher than
that of the corresponding portions of constitutive splice sites (SI
Table 3). This finding could reflect either that exonic sequences
generally have a higher GC content than intronic sequences (11) or
perhaps unknown mechanistic reasons related to the recognition
and splicing of dual splice sites.
One could argue that the resemblance of the dual splice site
matrix to both canonical 5 and 3 splice sitematrices of constitutive
splice sites may be an artifact of contamination with both types of
splice sites, which are erroneously classified as dual splice sites. To
exclude this possibility, we scored each individual dual splice site
with both canonical 5 and 3 splice site matrices, using methods
described in ref. 16 (see Materials and Methods for details).
As shown in Fig. 2, the canonical 5 and 3 splice sites of
constitutive exons fall into two distinct but overlapping populations
in the space of 5 and 3 splice site matrix scores. Most 5 splice sites
have low scores, using the PWM for 3 splice sites, and vice versa.
In contrast, dual splice sites have relatively high scores, using both
matrices (Fig. 2 A and C). For example, only 2–4% of constitutive
splice sites have both scores for a single site greater than the first
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Fig. 1. Illustrative representation of dual splicing. (A and B) Schematic
diagram of canonical splicing (A) and dual splicing (B). Boxes represent exons,
and lines are introns. The dual splice site is labeled in B. (C and D) The motifs
of canonical (constitutive) 5 and 3 splice sites (C) and of dual splice sites (D).
Dotted arrows and boxes indicate the similarity of dual sites with constitutive
splice sites. Uridine is shown as thymine in the logos.
Table 1. Percentage of dual splice sites conforming to the
AGGU rule.
Site All AGGU sites
5 splice site 27,556 15,455 (56.1%)
3 splice site 27,556 5,022 (18.2%)
dual site 594 155 (26.1%)
dual site.2 85 46 (54.1%)
dual site.3 40 28 (70.0%)
dual site.singleton 319 119 (37.3%)
dual site.singleton.2 39 31 (79.5%)
dual site.singleton.3 26 23 (88.5%)
dual site.2 (dual site.3), dual splice sites with two (three) or more supporting
transcripts for each isoform; dual site.singleton, singleton dual splice sites (no
other dual splice sites from the same gene). dual site.singleton.2 and dual
site.singleton.3 are similarly defined.
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quantile (0.25 in the abscissa in Fig. 2C), whereas50% (19 of 36)
of dual splice sites have both matrix scores greater than the same
threshold.
To ensure that this difference between constitutive and dual
splice sites is not an artifact reflecting our choice of dual splice sites
with the AGGU pattern, which conforms to the consensus of both
3 and 5 splice sites, we performed a stringent comparison of dual
splice sites to the subset of constitutive splice sites with the AGGU
pattern (Fig. 2 B and C). This increased the percentage of consti-
tutive splice sites with high scores by both PWMs, which neverthe-
less was still significantly lower than that of dual splice sites. For
example, only 8–13% of AGGU constitutive splice sites have both
scores greater than the first quantile, comparedwith50% for dual
splice sites (P 107 in both comparisons with 5 and 3 splice sites,
Fisher’s exact test).
Thus, the resemblance of dual splice sites to both 5 and 3 splice
site consensusmotifs strongly suggests that they are authentic splice
sites with dual specificity as both 5 and 3 splice sites. It is alsoworth
noting that relatively few dual splice sites have top scores (e.g.,
greater than the third quantile, 0.75 in the abscissa) for both
matrices (Fig. 2C), most likely reflecting the difficulty in simulta-
neously satisfying the constraints of both matrices in a perfect
manner.
Competitive Recognition Predicts Splicing Outcome.We further rea-
soned that if the dual splice sites are authentic, the sequence should
dictate the competition between 5 splice-site-associated and 3
splice-site-associated spliceosomal components, which would be
reflected in the relative use of each site and hence the number-of-
transcripts evidence for each isoform. The difference between 5
and 3 splice-site matrix scores of each dual splice site, b, reflects
the log-likelihood ratio of the site being recognized as a 5 splice site
to it being recognized as a 3 splice site (Eq. 2 in Materials and
Methods). We assumed a linear relationship between the binding-
likelihood ratios to splicing ratios and examined their Pearson
correlation. Indeed, we observed a significant correlation (R2 0.2,
P  0.006), which means that 20% of the variation in splicing
outcome can be explained by the binding affinity to the splice sites
(Fig. 3A). A simple classifier according to b at the threshold of
zero gives 26 of 36 (72%) correct predictions. This correlation and
accuracy of prediction is surprising, given that the number of
sequenced transcripts pooled from all sources is only an approxi-
mation of the real splicing outcome (17) and that other sequences
around the splice sites are also likely to be important determinants
of splice-site selection.
To test the latter hypothesis, we evaluated the importance of
upstream and downstream splice sites in determining splicing
outcome. We reasoned that the strength of the splice site that pairs
with the dual 5 or 3 splice site across the exon [as per exon
definition (6)] may influence the splicing outcome. For simplicity,
we limited our analysis to dual sites that give rise to alternative
exons, i.e., class II and class III, as defined above (see also SI Figs.
6 and 7). In the high-confidence dataset, 6 of 36 cases belong to this
category. To expand the sample size, we examined 109AGGUdual
sites with a single supporting transcript for either isoform, and with
perfect local alignment, and included nine additional cases in the
category. For each of the 15 cases in total, we calculated the scores
of the upstream3 splice site and downstream5 splice site, together
with the scores of the dual site, and derived a measure of compe-
tition b2 (see Eq. 3 in Materials and Methods for details). This
measure can have two alternative interpretations: the difference in
the strength of exon definition of the two isoforms or the difference
in the strength of alternative 5 and 3 splice-site competition. As
shown in Fig. 3B, the competitive recognition of dual splice sites
alonemeasured byb explains 19%of the variation, consistent with
the results in Fig. 3A, although the significance level drops because
of the limited sample size (P 0.1). A classifier according to b at
a threshold of zero gives 10 of 15 (67%) correct predictions.
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Fig. 2. Motif scores of dual and constitutive splice sites. (A) Graphical
representation of motif scores of constitutive 5 (blue), 3 (cyan), and dual (red)
splice sites. (B) Similar to analysis inA, except that only constitutive splice sites
with the AGGU pattern are shown. (C) Resemblance of dual splice sites to the
canonical 5 and 3 splice-site consensus motifs. Matrix scores were ranked and
converted into quantiles according to constitutive splice sites, and different
thresholds (quantile 0 to 1, in steps of 0.01) were applied to count the number
of sites whose scores exceed both thresholds.
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Fig. 3. Predicting splicing outcome, using binding specificity. Each point
represents a dual splice site. The x axes show the log-likelihood ratio of the
binding probabilities, and the y axes show the log ratio of supporting-
transcript number for the 5 splice-site isoform relative to that of the 3
splice-site isoform. (A) Competition at the dual splice site. The log-likelihood
ratio of binding is calculated as b by using the high-confidence dataset. (B)
Similar to A, except by using the extended set. (C) Competition by exon
definition or alternative 5/3 splice sites. The log-likelihood ratio of binding
is calculated as b2 by using the extended set.
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Importantly, including upstream and downstream splice sites in the
competition model explains 32% of the variation (P  0.03) (Fig.
3C). A classifier according to b2 at a threshold of zero gives 12 of
15 (80%) correct predictions. Therefore, we conclude that the
strength of the upstream and downstream splice sites, and probably
other regulatory sequences, also contributes to the dual splicing
pattern.
Splice Sites Are Used as Both 5 and 3 Splice Sites in Cells.To confirm
that dual splice sites are used as both 5 splice sites and 3 splice sites,
we analyzed splicing of the endogenous Smac/Diablo (DIABLO),
UBE2C, POLR2G, and UROD transcripts in two human cell lines.
In each case, RT-PCR analysis verified the presence of the two
isoforms with the expected sizes (Fig. 4 and SI Fig. 10; see primer
sequences in SI Table 4). Each pair of isoforms was identified in
HeLa cells and the neuronally derived Weri-Rb1 cell line. The use
of the predicted 5 and 3 splice sites of the Smac/Diablo and
UBE2C dual splice sites was further confirmed by sequence analysis
of the RT-PCR products (data not shown).
Dual splice sites are essentially alternative splice sites and are
potentially subject to regulation. We tested the relative use of the
Smac/Diablo and UBE2C dual 5 and 3 splice sites in a number of
tissues and cell lines.We observed variations in the use of the splice
sites (Fig. 4), suggesting that use of the dual splice sites is regulated.
If a specific trans-acting factor determines whether the site is used
as a 5 or 3 splice site, then a specific cell type or tissue might be
expected to show a general preference for the 5 or 3 splice site of
all dual splice sites.However, there did not appear to be a consistent
bias for the 5 or 3 splice site in any of the tissues or cell types we
tested for the two pre-mRNAs we examined.
To explore the functional implications of dual splicing, we
examined the splicing patterns that can potentially generate func-
tional protein products (SI Table 2). In six cases (17%), we found
protein products for both isoforms, and the alternatively spliced
region of each isoform was at least partially coding. In 21 cases,
protein products for one or both isoforms were not found, most
likely because of the incompleteness of the protein sequence
database in GenBank (18) and/or because of the presence of
premature termination codons in some isoforms that are presum-
ably subject to nonsense-mediated mRNA decay (19). In the
remaining cases, the dual splice sites were in the untranslated
regions, making it difficult to link transcripts to protein sequences
directly, although protein sequences that are compatible with the
transcripts were found.
Dual Splice Sites inMouse.Dual splice sites are not limited to human:
We also found evidence for 195 putative dual splice sites in mouse.
Using the same filtering criteria as applied in human, the mouse
high-confidence dataset contains 18 sites (SI Table 5). The differ-
ence in number is likely because EST coverage in human is
significantly higher than that in mouse (7 million compared with 4
million). Dual splice sites were also detected in rat, zebrafish, and
fly, although infrequently and with less supporting evidence (data
not shown). We performed a detailed analysis of mouse dual splice
sites in the same way as we did for human. The properties of mouse
dual splice sites, such as the motif itself, were generally very similar
to those of human sites (data not shown). We performed a
human–mouse comparison by examining the conservation of dual-
splice-site sequences and the splicing patterns. Although the splice
sites are often conserved at the sequence level, it appears that the
conservation of flanking exonic and/or intronic sequences is low (SI
Figs. 5–9 and data not shown). Most of the sites lack supporting
evidence for conservation of the dual splicing pattern, except in two
cases:MYL6 andPHC (SI Figs. 11 and 12). Both of these sites follow
theAGGUrule in both species. However, neither of these two sites
was included in our high-confidence set because of an insufficient
number of supporting transcripts. Therefore, the conservation rate
in dual splicing appears to be very low, with an upper bound of 5%
[2 of 38 (36  2)], which is much lower than that of cassette-type
splicing events (10–20%) (20–22). Indeed, we could only detect a
single isoform of Smac/Diablo and UBE2C in the mouse neuronal
cell line NSC-34 and in mouse NIH 3T3 fibroblasts (Fig. 4).
Discussion
Large-scale sequencing projects in the past decade and recent
applications of splicing microarrays have made clear the extent and
complexity of AS in mammalian genes (23). In this study, we
identify a class of splice site and associatedASpattern.A dual splice
site is a composite of canonical 5 and 3 splice sites, which makes
it possible for a single site to be recognized as either a 5 splice site
or a 3 splice site and results in an exon becoming an intron and vice
versa (exon/intron flipping). There was only one previously docu-
mented example of a dual-specificity splice site in the IRF3 gene
(24). In this case, dual splicing generates isoforms that can poten-
tially code for proteins with different functions. We show that this
form of AS is more prevalent than previously appreciated. We
identified hundreds of potential dual splice sites in human and
mouse, among which at least 36 in human and 18 in mouse were
identified with high confidence. The greatly expanded list of dual
sites allowed us to uncover unique features of these sites.
Several lines of evidence, including multiple supporting tran-
scripts, the resemblance of the sites to both 5 and 3 splice site
consensus motifs, the correlation between binding specificity and
splicing outcome, and the presence in different species, strongly
suggest that AS via dual sites is an authentic pattern. For several
cases, the presence of these sites and the splicing pattern were
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Fig. 4. Validation of dual-splice-site recognition in human and mouse.
RT-PCR analysis of RNA from human brain (b), testis (te), tonsil (to), and thymus
(th) tissues (Clontech) and HeLa (H), Weri-Rb1(W), NIH 3T3 (3), and NSC-34 (N)
cells. Diagram (A–C) of the general splicing pattern and location of primers
(arrowheads) used to detect isoforms that result from the use of the 5 splice
site or 3 splice site of Smac/Diablo (3ss, 234 nt; 5ss, 205 nt) (B) andUBE2C (3ss,
287 nt; 5ss, 233 nt) (C). In the case of UBE2C, the exon containing the dual
splice site is also skipped to give an additional isoform (skip, 82 nt). (D)
Quantitative analysis of RT-PCR results. The histogram represents the percent-
age of the products that are generated by use of the 5 splice site.
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further validated by RT-PCR and sequencing. It is possible that
many of the dual splice sites not included in our high-confidence
dataset are also authentic but currently have a limited number of
supporting ESTs or mRNA transcripts for reasons implicit in the
splicing event. For example, the AS events associated with the use
of the 5 or 3 splice site may be rare in certain tissues, or one of the
splicing events may generate a premature termination codon,
resulting in a transcript that is subject to nonsense-mediatedmRNA
decay.
The capacity of a dual splice site to switch its identity between a
5 splice site and a 3 splice site has implications for many aspects
of pre-mRNA processing and raises important questions regarding
the mechanisms of splice-site recognition, regulation, and compe-
tition. First, to our knowledge, dual splice sites are the first type of
splice site to lack unambiguous identity as either a 5 or a 3 splice
site. The use of a dual splice site likely involves competition between
the 5 and 3 splice sites through a stochastic process, as the two
isoforms can coexist in the same tissue type. It is of interest to know
at which step of spliceosome assembly the choice of 5 or 3 splice
site is made. Second, what are the determinants of dual-splice-site
use? Except for two cases, the dual AS pattern does not appear to
be conserved between human and mouse. However, in many cases,
including two that we tested (Fig. 4), the sequence of the dual splice
site is conserved. Despite this sequence conservation, the sites do
not appear to be used as dual splice sites in mouse. In fact,
thousands of splice sites have dual character comparable with the
observed dual splice sites, but they do not appear to have dual
splicing. Our preliminary analysis suggests that the flanking splice
sites also contribute to the splicing outcome, together with the dual
sites. Other splicing signals, such as the strength of the polyrimidine
tract and the distribution of splicing enhancers and silencers, are
also likely important determinants of dual-splice-site use.
At the present time, the functional significance of this unusualAS
pattern is not clear. Our results suggest that most dual splice sites
have a recent evolutionary history, appearing independently in each
species. Recently, introns with significant sequence similarities at
their 5 and 3 splice sites were described in ref. 25. It was proposed
that sequences bearing cryptic splice sites can be duplicated to serve
as the termini of a new intron. Such a mechanism could be one
possible evolutionary origin of dual splice sites before the dupli-
cated cryptic splice sites had a chance to evolve into unambiguous
5 or 3 splice sites.
As with other AS patterns, many of the new isoforms might have
arisen as splicing errors or may represent evolutionary precursors
(26). However, by inserting an exon and simultaneously deleting
another exon, dual splicing may in some cases generate a transcript
with adaptive value and thus serve as a mechanism for genomic
diversification and expansion of coding capacity. In some cases,
both isoforms appear to be abundant. For instance, there are 344
transcripts aligned to theWDR73 locus, among which 43 (13%) and
99 (29%) directly support one of the two isoforms resulting from
dual splicing, respectively. In addition to cases that are predicted to
yield unproductive transcripts by inducing nonsense-mediated
mRNA decay, we found several cases, including Smac/Diablo and
UBE2C, in which both isoforms code for distinct protein products
with potentially altered biochemical properties (SI Table 2). Our
RT-PCR analysis reveals that both isoforms of Smac/Diablo and
UBE2C are abundant at the mRNA level. Furthermore, the levels
of each isoform vary among tissues and cell types, suggesting
regulation of the use of the dual splice site as a functional 5 or 3
splice site. This regulation may have important functional conse-
quences for protein activity. In the case of Smac/Diablo, which
codes for a proapoptotic protein, the alternative isoforms have
different abilities to bind to effector molecules and differential
cellular localization, although the dual splicing was not previously
noted (27).
There are interesting similarities and differences between dual
splice sites and the recursive splice sites reported in refs. 28 and 29,
which are thought to be used as intermediate steps in the splicing
of long introns. The consensus motifs for both types of splice sites
look like a composite of the canonical 5 and 3 splice-site consensus
motifs. However, in reported examples of recursive splicing, a splice
site first functions as a 3 splice site, and then, after ligation to the
upstream exon, a 5 splice site is regenerated. This new 5 splice site
is subsequently spliced to a downstream 3 splice site. Thus,
recursive splice sites are generated, in part, as a result of the splicing
reaction, in contrast to dual splice sites, for which both the 5 and
3 splice sites are present in the pre-mRNA and are functional.
Another difference between these two classes of splice sites is
that recursive splicing at intronic sites does not directly affect the
final mRNA product, whereas AS of dual splice sites does. In
addition, although in principle the two sequential steps of recursive
splicing might be reversed, with a 5 splice site used first and
regenerating a functional 3 splice site, a recent study argued against
this reversibility (29). Therefore, competition is not involved in
recognition of the recursive splice site as a 5 or 3 splice site in the
first splicing reaction because only one functional splice site is
initially present and used. In contrast, for dual splice sites, both the
5 splice site and the 3 splice site are present simultaneously and
probably compete for binding of their respective splicing factors.
Steric hindrance presumably forces the use of a dual site in a given
pre-mRNAmolecule as either a 5 or 3 splice site because once 3
splice-site factors bind to the site, 5 splice-site factors are effectively
excluded, and vice versa, a consideration that also applies to
microexons (30).
Despite the above differences, it is possible that some dual splice
sites could function as sites of recursive splicing as well. For 10 of
36 high-confidence dual splice sites, there is transcript evidence that
the exon in which the dual splice site resides can be skipped (e.g.,
Fig. 4 A and C). Recursive splicing at a dual splice site would result
in an mRNA isoform lacking an exon, which would be indistin-
guishable from a mature mRNA arising from a conventional
exon-skipping event. Examples of recursive splicing resulting in
exon skipping are described in refs. 28 and 29. More direct
experimental evidence will be required to determine whether exon
skipping is actually generated by recursive splicing at the dual splice
sites we found.
In summary, by using transcripts and genome alignment in
human and mouse and experimental validation, we have identified
and characterized a class of splice sites with dual specificity as 5 and
3 splice sites. The functional significance of these sites and of the
AS events they specify is underscored by their direct effects on the
corresponding protein products, in some cases in a tissue-specific
manner. Importantly, this class of AS via dual splice sites suggests
even greater versatility of the splicing machinery than was previ-
ously recognized.
Materials and Methods
Detection of Splicing Patterns with Splicing Graphs. We built a
database of classified AS events (dbCASE; http://rulai.cshl.edu/
dbCASE), using high-quality transcripts (mRNA/EST) and ge-
nome alignment for human and mouse (coverage 85%, identity
95%). Briefly, transcripts from UniGene (ftp://ftp.ncbi.nih.gov/
repository/UniGene, build 196 for human, build 158 formouse) and
RefSeq (ftp://ftp.ncbi.nih.gov/refseq/release, release 20) (31) were
aligned to genomic sequences (hg18 and mm8) by using sim4 (32).
The alignment of all transcripts to the same gene locus was then
converted into a splicing graph, in which each splice site is repre-
sented by a node and each exon/intron is represented by an edge
(13). In contrast to Sugnet et al. (13), we allowed the same position
to be both 5 and 3 splice site, and the transcript evidence was
recorded for each form separately, which was critical for this study.
AS patterns (in particular dual-specificity splice sites) were detected
by analyzing subnetwork topologies. In addition, strictly constitutive
exon and introns (in the sense of no violation of transcript evidence)
can be detected efficiently by graphic analysis.
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Construction of PWMs for Canonical and Dual Splice Sites.Tomeasure
the presumptive binding specificity of the spliceosome, we first
constructed PWMs for canonical 5 and 3 splice sites from
constitutively spliced exons (27,556 in human and 36,262 in mouse,
with four or more supporting transcripts). Thirty nucleotides sur-
rounding the splice junction (15 nt on each side)were extracted, and
PWMs were built from these sequences (16). Each dual splice site,
as well as constitutive splice site, was scored by both matrices as
follows:
S5ss i log2	 f i,bi5ss /f bi0 
 [1A]
and
S3ss i log2	 f i,bi3ss /f bi0 
 , [1B]
where s5ss (s3ss) is the score of the 5 (or 3) splice site matrix,
i is the position in the matrix, and bi is the base of the site at
position i. fi,bi
5ss, fi,bi
3ss, and f bi
0 represent the frequency of base bi
in 5 splice sites, 3 splice sites, and background sequences,
respectively. A matrix of dual splice sites was built in a similar
manner.
Competition at Dual Splice Sites or by Exon Definition.Weconsidered
two models of competition to determine the splicing outcome at a
dual splice site. In the first model, the recognition of the dual splice
site as a 5 or 3 splice site results from the competition of 5
splice-site-associated and 3 splice-site-associated spliceosomal
components at the dual splice site. Therefore, the difference
between 5 and 3 splice site matrix scores of each dual splice site
reflects the log-likelihood ratio of the site being recognized as a 5
splice site to it being recognized as a 3 splice site.
b S5ss S3ss i log2 	 f i,bi5ss/f i,bi3ss
  log2P	5ss
 /P	3ss

[2]
In the secondmodel, the splicing outcome results from competition
between exon definition by pairing the dual splice site with the
upstream 3 splice site or with the downstream 5 splice site (Fig.
1B). The competition is represented by
b2 	Sup
3ss Sdual
5ss 
 	Sdual
3ss  Sdown
5ss 

 	Sdual
5ss  Sdown
5ss 
 	Sdual
3ss  Sup
3ss
, [3]
where the scores of the dual sites are shown by the subscripts, Sup
3ss
is the matrix score of the upstream 3 splice site, and sdown
5ss is the
matrix score of the downstream 5 splice site. An alternative
interpretation of this model is the difference in the strength of
alternative 5 (3) splice-site competition, as shown on the bottom
part of Eq. 3.
Identification of Protein Products. For each dual splice site, repre-
sentative supporting transcripts were retrieved from dbCASE and
searched against the nonredundant protein database of GenBank
(18). All protein sequences with significant matches (10 aa) were
retrieved and BLATed against the genomic sequence in the UCSC
genome browser (http://genome.ucsc.edu) (33). The protein se-
quences that aligned properly with the desired pattern were sub-
sequently identified.
Statistical Analysis. Fisher’s exact test in R was used to evaluate the
significance of 2  2 contingency tables (34).
RT-PCR. RNA collected from cells by using TRIzol Reagent (In-
vitrogen, Carlsbad, CA) or RNA from tissue samples (Clontech,
Mountain View, CA) was reverse transcribed by using SuperScript
II reverse transcriptase (Invitrogen) with oligo(dT) primers. PCR
with AmpliTaq Gold (Roche, Indianapolis, IN) was carried out for
40 amplification cycles (95°C for 30 s, 60°C for 60 s, and 72°C for
60 s) in reactions containing [-32P]dCTP. Primer sequences are
provided in SI Table 4. Products were separated on 6% native
polyacrylamide gels. Quantitation was based on phosphorimage
analysis (FLA-5100; Fujifilm, Valhalla, NY).
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